LONDON and GIRONA, Spain, Aug. 4, 2023 /PRNewswire/ -- Accord Healthcare, Ltd. (Accord) and HIPRA, today announced that they have entered into an exclusive distribution agreement to commercialise HIPRA's COVID-19 vaccine in the United Kingdom (UK). The vaccine was fully developed in the European Union (EU) and consists of a bivalent adjuvanted vaccine containing a recombinant protein1. HIPRA's COVID vaccine, Bimervax®, was authorised by the UK MHRA on July 31st, 2023, as a booster for active immunisation to prevent COVID-19 in individuals 16 years of age and older who have previously received a mRNA COVID-19 vaccine1,2. The main trial compared the immune response triggered by HIPRA's vaccine with that triggered by the Comirnaty® mRNA vaccine (Pfizer/BioNTech)3. Following the results, the UK MHRA and EMA concluded that the benefits of HIPRA's vaccine outweigh its risks and recommended the granting of the marketing authorisation in the UK and the EU zone countries, respectively2,4.
The Health Emergency Preparedness and Response Authority (HERA) of the European Commission (EC) has entered a co-procurement framework contract for HIPRA HUMAN HEALTH’s bivalent recombinant protein Covid-19 vaccine.
BRUSSELS/BARCELONA, Aug 2 (Reuters) - The European Commission said on Tuesday it had signed a joint procurement contract with Spanish pharmaceutical firm HIPRA for the supply of its protein COVID-19 vaccine, which will be available if approved by the European Medicines Agency (EMA).
March 29 (Reuters) - Europe's drug regulator said on Tuesday it had started a real-time review of Spanish pharmaceutical firm Hipra's COVID-19 vaccine candidate.
MADRID, Feb 1 (Reuters) - The Spanish medicines agency said on Tuesday it had authorised pharmaceutical firm Hipra to carry out phase III trials of the COVID-19 vaccine it is developing
MADRID (Reuters) -Spain’s medicines agency has authorised Catalonia-based pharmaceutical group Hipra to test a COVID-19 vaccine it is developing on more than 1,000 volunteers, Prime Minister Pedro Sanchez said on Monday.